Publications by authors named "Colby S Shemesh"

Claim this Profile
T
Tiragolumab in combination with atezolizumab and bevacizumab in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (MORPHEUS-Liver): a randomised, open-label, phase 1b-2, study.
Richard S Finn, Baek-Yeol Ryoo, Chih-Hung Hsu, Daneng Li, Adam M Burgoyne, Colby S Shemesh

Lancet Oncol· February 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
PARP inhibition with rucaparib alone followed by combination with atezolizumab: Phase Ib COUPLET clinical study in advanced gynaecological and triple-negative breast cancers.
Rebecca Kristeleit, Alexandra Leary, Ana Oaknin, Andres Redondo, Angela George, Colby S Shemesh

Br J Cancer· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I pharmacokinetic, safety, and preliminary efficacy study of tiragolumab in combination with atezolizumab in Chinese patients with advanced solid tumors.
Colby S Shemesh, Yongsheng Wang, Andrew An, Hao Ding, Phyllis Chan

Cancer Chemother Pharmacol· July 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics (PK) of Tiragolumab in First-in-Human Study in Patients with Mixed Solid Tumors (GO30103).
Elena Garralda, Do Youn Oh, Antoine Italiano, Philippe L Bedard, Jean-Pierre Delord, Colby S Shemesh

J Clin Pharmacol· May 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Applying Natural Language Processing to ClinicalTrials.gov: mRNA cancer vaccine case study.
Bianca Vora, Denison Kuruvilla, Chloe Kim, Michael Wu, Colby S Shemesh

Clin Transl Sci· December 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab plus Magrolimab, Niraparib, or Tocilizumab versus Atezolizumab Monotherapy in Platinum-Refractory Metastatic Urothelial Carcinoma: A Phase Ib/II Open-Label, Multicenter, Randomized Umbrella Study (MORPHEUS Urothelial Carcinoma).
Alexandra Drakaki, Thomas Powles, Aristotelis Bamias, Juan Martin-Liberal, Sang Joon Shin, Colby S Shemesh

Clin Cancer Res· November 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Early Decision Making in a Randomized Phase II Trial of Atezolizumab in Biliary Tract Cancer Using a Tumor Growth Inhibition-Survival Modeling Framework.
Colby S Shemesh, Phyllis Chan, Mathilde Marchand, Antonio Gonçalves, Shweta Vadhavkar

Clin Pharmacol Ther· September 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab Plus PEGPH20 Versus Chemotherapy in Advanced Pancreatic Ductal Adenocarcinoma and Gastric Cancer: MORPHEUS Phase Ib/II Umbrella Randomized Study Platform.
Andrew H Ko, Kyu-Pyo Kim, Jens T Siveke, Charles D Lopez, Jill Lacy, Colby S Shemesh

Oncologist· June 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Development of a pediatric physiologically-based pharmacokinetic model to support recommended dosing of atezolizumab in children with solid tumors.
Weize Huang, Felix Stader, Phyllis Chan, Colby S Shemesh, Yuan Chen

Front Pharmacol· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacology-based ranking of anti-cancer drugs to guide clinical development of cancer immunotherapy combinations.
Vincent Lemaire, Colby S Shemesh, Anand Rotte

J Exp Clin Cancer Res· October 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region.
Colby S Shemesh, Phyllis Chan, Hui Shao, Derek-Zhen Xu, Daniel Combs

Liver Cancer· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Personalized Cancer Vaccines: Clinical Landscape, Challenges, and Opportunities.
Colby S Shemesh, Joy C Hsu, Iraj Hosseini, Ben-Quan Shen, Anand Rotte

Mol Ther· February 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pan-cancer population pharmacokinetics and exposure-safety and -efficacy analyses of atezolizumab in patients with high tumor mutational burden.
Colby S Shemesh, Phyllis Chan, Fatema A Legrand, David S Shames, Meghna Das Thakur

Pharmacol Res Perspect· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Application of a Two-Analyte Integrated Population Pharmacokinetic Model to Evaluate the Impact of Intrinsic and Extrinsic Factors on the Pharmacokinetics of Polatuzumab Vedotin in Patients with Non-Hodgkin Lymphoma.
Dan Lu, Tong Lu, Rong Shi, Leonid Gibiansky, Priya Agarwal, Colby S Shemesh

Pharm Res· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of polatuzumab vedotin in combination with R/G-CHP in patients with B-cell non-Hodgkin lymphoma.
Colby S Shemesh, Priya Agarwal, Tong Lu, Calvin Lee, Randall C Dere

Cancer Chemother Pharmacol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Integrated Two-Analyte Population Pharmacokinetic Model of Polatuzumab Vedotin in Patients With Non-Hodgkin Lymphoma.
Dan Lu, Tong Lu, Leonid Gibiansky, Xiaobin Li, Chunze Li, Colby S Shemesh

CPT Pharmacometrics Syst Pharmacol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Atezolizumab for children and young adults with previously treated solid tumours, non-Hodgkin lymphoma, and Hodgkin lymphoma (iMATRIX): a multicentre phase 1-2 study.
Birgit Geoerger, C Michel Zwaan, Lynley V Marshall, Jean Michon, Franck Bourdeaut, Colby S Shemesh

Lancet Oncol· January 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Population pharmacokinetics, exposure-safety, and immunogenicity of atezolizumab in pediatric and young adult patients with cancer.
Colby S Shemesh, Pascal Chanu, Kris Jamsen, Russ Wada, Gianluca Rossato

J Immunother Cancer· November 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of the Drug Interaction Potential of Unconjugated and GalNAc-Conjugated 2'-MOE-ASOs.
Colby S Shemesh, Rosie Z Yu, Mark S Warren, Michael Liu, Mirza Jahic

Mol Ther Nucleic Acids· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetic and Pharmacodynamic Investigations of ION-353382, a Model Antisense Oligonucleotide: Using Alpha-2-Macroglobulin and Murinoglobulin Double-Knockout Mice.
Colby S Shemesh, Rosie Z Yu, Hans J Gaus, Punit P Seth, Eric E Swayze

Nucleic Acid Ther· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disposition and Pharmacology of a GalNAc3-conjugated ASO Targeting Human Lipoprotein (a) in Mice.
Rosie Z Yu, Mark J Graham, Noah Post, Stan Riney, Thomas Zanardi, Colby S Shemesh

Mol Ther Nucleic Acids· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Elucidation of the Biotransformation Pathways of a Galnac3-conjugated Antisense Oligonucleotide in Rats and Monkeys.
Colby S Shemesh, Rosie Z Yu, Hans J Gaus, Sarah Greenlee, Noah Post

Mol Ther Nucleic Acids· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thermosensitive liposome formulated indocyanine green for near-infrared triggered photodynamic therapy: in vivo evaluation for triple-negative breast cancer.
Colby S Shemesh, Delaram Moshkelani, Hailing Zhang

Pharm Res· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Indocyanine green loaded liposome nanocarriers for photodynamic therapy using human triple negative breast cancer cells.
Colby S Shemesh, Claire W Hardy, David S Yu, Brian Fernandez, Hailing Zhang

Photodiagnosis Photodyn Ther· June 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Near-infrared image-guided delivery and controlled release using optimized thermosensitive liposomes.
David C Turner, Delaram Moshkelani, Colby S Shemesh, David Luc, Hailing Zhang

Pharm Res· August 2012

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis